High dosage desferrioxamine therapy in a female patient with acquired aplastic anaemia and transfusion siderosis

A 32 year old woman with severe aplastic anaemia required frequent transfusions and consequently developed hyperferrioxaemia (54 microMol/l) and hyperferritinaemia (1,700 ng/ml). For the treatment of transfusion siderosis she was given 18 high dose courses each comprising 35 g of desferrioxamine. Be...

Full description

Saved in:
Bibliographic Details
Published in:Blut 1986-04, Vol.52 (4), p.211-219
Main Authors: Breithaupt, H, Heckers, H, Pralle, H, Guttmann, W, Bleyl, H, Graef, V, Jundt, G
Format: Article
Language:English
Subjects:
Adult
Anemia, Aplastic - pathology
Anemia, Aplastic - therapy
Bone Marrow - pathology
Deferoxamine - administration & dosage
Deferoxamine - adverse effects
Feces - metabolism
Female
Ferritins - blood
Humans
Iron - metabolism
Siderosis - drug therapy
Siderosis - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 32 year old woman with severe aplastic anaemia required frequent transfusions and consequently developed hyperferrioxaemia (54 microMol/l) and hyperferritinaemia (1,700 ng/ml). For the treatment of transfusion siderosis she was given 18 high dose courses each comprising 35 g of desferrioxamine. Because of pre-existing thrombocytopenia (platelet count 5 X 10(9)/l) the iron chelating agent was given by continuous intravenous infusion over 3 1/2 days. High dose desferrioxamine had to be abandoned because of severe bone pain. The desferrioxamine infusions achieved a negative iron balance, iron loss after each infusion being 100 to 200 mg in the urine and 400 mg in the faeces. Serum iron and ferritin concentrations fell almost to normal. This report shows that faecal iron excretion must be taken into account in assessing the balance of iron input and output during desferrioxamine treatment.
ISSN:0006-5242
1432-0584
DOI:10.1007/BF00321080